Cargando…
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
BACKGROUND: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We hypothesised that the functional role of c-MYC differ...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984797/ https://www.ncbi.nlm.nih.gov/pubmed/26954716 http://dx.doi.org/10.1038/bjc.2016.46 |
_version_ | 1782447991152443392 |
---|---|
author | Green, Andrew R Aleskandarany, Mohammed A Agarwal, Devika Elsheikh, Somaia Nolan, Christopher C Diez-Rodriguez, Maria Macmillan, R Douglas Ball, Graham R Caldas, Carlos Madhusudan, Srinivasan Ellis, Ian O Rakha, Emad A |
author_facet | Green, Andrew R Aleskandarany, Mohammed A Agarwal, Devika Elsheikh, Somaia Nolan, Christopher C Diez-Rodriguez, Maria Macmillan, R Douglas Ball, Graham R Caldas, Carlos Madhusudan, Srinivasan Ellis, Ian O Rakha, Emad A |
author_sort | Green, Andrew R |
collection | PubMed |
description | BACKGROUND: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We hypothesised that the functional role of c-MYC differs between molecular subtypes of BCs. METHODS: We therefore investigated the correlation between c-MYC protein expression and other proteins involved in different cellular functions together with clinicopathological parameters, patients' outcome and treatments in a large early-stage molecularly characterised series of primary invasive BCs (n=1106) using immunuohistochemistry. The METABRIC BC cohort (n=1980) was evaluated for MYC mRNA expression and a systems biology approach utilised to identify genes associated with MYC in the different BC molecular subtypes. RESULTS: High MYC and c-MYC expression was significantly associated with poor prognostic factors, including grade and basal-like BCs. In luminal A tumours, c-MYC was associated with ATM (P=0.005), Cyclin B1 (P=0.002), PIK3CA (P=0.009) and Ki67 (P<0.001). In contrast, in basal-like tumours, c-MYC showed positive association with Cyclin E (P=0.003) and p16 (P=0.042) expression only. c-MYC was an independent predictor of a shorter distant metastases-free survival in luminal A LN+ tumours treated with endocrine therapy (ET; P=0.013). In luminal tumours treated with ET, MYC mRNA expression was associated with BC-specific survival (P=0.001). In ER-positive tumours, MYC was associated with expression of translational genes while in ER-negative tumours it was associated with upregulation of glucose metabolism genes. CONCLUSIONS: c-MYC function is associated with specific molecular subtypes of BCs and its overexpression confers resistance to ET. The diverse mechanisms of c-MYC function in the different molecular classes of BCs warrants further investigation particularly as potential therapeutic targets. |
format | Online Article Text |
id | pubmed-4984797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49847972017-04-12 MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours Green, Andrew R Aleskandarany, Mohammed A Agarwal, Devika Elsheikh, Somaia Nolan, Christopher C Diez-Rodriguez, Maria Macmillan, R Douglas Ball, Graham R Caldas, Carlos Madhusudan, Srinivasan Ellis, Ian O Rakha, Emad A Br J Cancer Molecular Diagnostics BACKGROUND: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We hypothesised that the functional role of c-MYC differs between molecular subtypes of BCs. METHODS: We therefore investigated the correlation between c-MYC protein expression and other proteins involved in different cellular functions together with clinicopathological parameters, patients' outcome and treatments in a large early-stage molecularly characterised series of primary invasive BCs (n=1106) using immunuohistochemistry. The METABRIC BC cohort (n=1980) was evaluated for MYC mRNA expression and a systems biology approach utilised to identify genes associated with MYC in the different BC molecular subtypes. RESULTS: High MYC and c-MYC expression was significantly associated with poor prognostic factors, including grade and basal-like BCs. In luminal A tumours, c-MYC was associated with ATM (P=0.005), Cyclin B1 (P=0.002), PIK3CA (P=0.009) and Ki67 (P<0.001). In contrast, in basal-like tumours, c-MYC showed positive association with Cyclin E (P=0.003) and p16 (P=0.042) expression only. c-MYC was an independent predictor of a shorter distant metastases-free survival in luminal A LN+ tumours treated with endocrine therapy (ET; P=0.013). In luminal tumours treated with ET, MYC mRNA expression was associated with BC-specific survival (P=0.001). In ER-positive tumours, MYC was associated with expression of translational genes while in ER-negative tumours it was associated with upregulation of glucose metabolism genes. CONCLUSIONS: c-MYC function is associated with specific molecular subtypes of BCs and its overexpression confers resistance to ET. The diverse mechanisms of c-MYC function in the different molecular classes of BCs warrants further investigation particularly as potential therapeutic targets. Nature Publishing Group 2016-04-12 2016-03-08 /pmc/articles/PMC4984797/ /pubmed/26954716 http://dx.doi.org/10.1038/bjc.2016.46 Text en Copyright © 2016 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Molecular Diagnostics Green, Andrew R Aleskandarany, Mohammed A Agarwal, Devika Elsheikh, Somaia Nolan, Christopher C Diez-Rodriguez, Maria Macmillan, R Douglas Ball, Graham R Caldas, Carlos Madhusudan, Srinivasan Ellis, Ian O Rakha, Emad A MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours |
title | MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours |
title_full | MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours |
title_fullStr | MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours |
title_full_unstemmed | MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours |
title_short | MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours |
title_sort | myc functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984797/ https://www.ncbi.nlm.nih.gov/pubmed/26954716 http://dx.doi.org/10.1038/bjc.2016.46 |
work_keys_str_mv | AT greenandrewr mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT aleskandaranymohammeda mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT agarwaldevika mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT elsheikhsomaia mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT nolanchristopherc mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT diezrodriguezmaria mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT macmillanrdouglas mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT ballgrahamr mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT caldascarlos mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT madhusudansrinivasan mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT ellisiano mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours AT rakhaemada mycfunctionsarespecificinbiologicalsubtypesofbreastcancerandconfersresistancetoendocrinetherapyinluminaltumours |